AGTC Announces Updated Development Plan for Its X-Linked Retinitis Pigmentosa Clinical Program (Globe Newswire)

AGTC Announces Updated Development Plan for Its X-Linked Retinitis Pigmentosa Clinical Program

UF startup and UF Innovate | Sid Martin Biotech alum Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, announced next steps in the clinical development of the company’s potential treatment of X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene following receipt of written feedback from the FDA.

The revised development plan, which includes immediate expansion of the current trial in parallel with the planned Phase 2/3 trial, will be designed to evaluate sustained efficacy across multiple measures of potential benefit in patients with XLRP. 

“We are pleased with the productive feedback from the FDA and are modifying our development program based on their recommendations to advance our XLRP gene therapy candidate,” said Sue Washer, president and CEO of AGTC.

Learn more about AGTC Announces Updated Development Plan for Its X-Linked Retinitis Pigmentosa Clinical Program.
X